Merck KGaA (FRA:MRK) has been given a €100.00 ($116.28) target price by stock analysts at Commerzbank in a research report issued on Thursday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Commerzbank’s price objective would suggest a potential upside of 5.42% from the company’s current price.
Several other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Merck KGaA in a research note on Wednesday, September 19th. Kepler Capital Markets set a €106.00 ($123.26) target price on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, October 10th. Barclays set a €72.00 ($83.72) target price on Merck KGaA and gave the company a “sell” rating in a research note on Tuesday, October 9th. UBS Group set a €115.00 ($133.72) price target on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, October 17th. Finally, Sanford C. Bernstein set a €105.00 ($122.09) price target on Merck KGaA and gave the stock a “buy” rating in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of €98.16 ($114.14).
FRA MRK opened at €94.86 ($110.30) on Thursday. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.